Metabolic & GLP-1

1. Metabolic & GLP-1well supported · human dataAdded 11 August 2026

   Diet and exercise cooled inflammation, not just waistlines, in metabolic syndrome

   Across six randomised trials of 1246 overweight or obese adults with metabolic syndrome, 6 to 12 months of diet and physical activity change reduced waist circumference by 3.12 cm on average and lowered the inflammatory markers C-reactive protein and IL-6, while raising adiponectin.

   ⚠What it shows: A consistent direction of travel: results pooled from six trials in 1246 adults with metabolic syndrome, all lasting 6 to 12 months, favoured lifestyle change on every marker measured. The authors still want higher-quality studies before the inflammation findings are treated as settled.Meta-analysis · Biol Res Nurs

   Full breakdown →Metabolic syndrome explained →Metabolic Fitness Index →Effects of Lifestyle Intervention on Inflammatory Markers and Waist Circumference in Overweight/Obese Adults With Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Biol Res Nurs 2022
2. Metabolic & GLP-1preliminary · human dataAdded 11 August 2026

   A daily GLP-1 pill cut body weight by up to 11.3% in 36 weeks

   In a 36-week mid-stage trial of 230 adults with obesity or overweight, the once-daily oral GLP-1 pill aleniglipron produced up to 11.3% more weight loss than placebo, with mostly mild to moderate gut side effects.

   ⚠What it shows: Promising but not final: one 36-week trial in 230 adults, run and part-authored by the drug's developer, so the result needs confirming in the larger late-stage trials that decide whether a medicine gets approved.Study · Nat Med

   Full breakdown →Energy balance explained →Calorie Deficit Calculator →Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med 2026
3. Metabolic & GLP-1well supported · human dataAdded 11 August 2026

   Lifting alone moves cholesterol in the right direction

   Strength training on its own reduced total cholesterol, triglycerides, LDL cholesterol and C-reactive protein in adults, while raising HDL cholesterol and adiponectin, in a meta-analysis of trials comparing lifting with no exercise.

   ⚠What it shows: Solid pooled evidence: results pooled from many adult trials comparing lifting alone with a group that did not train, and all six blood markers moved the right way. The shifts were small to moderate, and the search only runs to May 2017, so newer trials are missing.Meta-analysis · J Phys Act Health

   Full breakdown →ApoB explained →Heart Age Calculator →Effect of Strength Training on Lipid and Inflammatory Outcomes: Systematic Review With Meta-Analysis and Meta-Regression. J Phys Act Health 2019
4. Metabolic & GLP-1well supported · human dataAdded 10 August 2026

   Hard cardio beats weights for shrinking visceral fat

   Vigorous aerobic exercise and HIIT ranked most likely to be the best interventions for reducing visceral fat in a pooled comparison of 84 randomised trials covering 4836 adults with overweight or obesity. Resistance training ranked least effective and did not reduce visceral fat in women or in people with body fat of 40% or more.

   ⚠What it shows: About as broad as exercise evidence gets: 84 trials and 4836 adults with overweight or obesity, pooled and ranked against each other. The rankings reflect the probability of being best rather than certainty, and why lifting failed to shift visceral fat in women needs more study.Meta-analysis · Obes Rev

   Full breakdown →Visceral fat explained →Heart Rate Zone Calculator →Effects of various exercise types on visceral adipose tissue in individuals with overweight and obesity: A systematic review and network meta-analysis of 84 randomized controlled trials. Obes Rev 2024
5. Metabolic & GLP-1preliminary · human dataAdded 10 August 2026

   The trendy TyG index adds almost nothing to standard heart risk scores

   The triglyceride-glucose index, a cheap marker built from routine blood tests, was linked with roughly double the cardiovascular risk in a Chinese cohort, yet adding it to the Framingham Risk Score barely improved prediction, and pooled results across five cohorts found a negligible gain.

   ⚠What it shows: A useful corrective rather than a final word: one Chinese study following adults aged 45 to 80, plus results pooled from five similar studies, none of which tested the marker in a trial. The authors themselves rated the certainty on the prediction question as very low.Study · Front Cardiovasc Med

   Full breakdown →Insulin sensitivity explained →Heart Age Calculator →Reassessing of the incremental predictive value of triglyceride-glucose index beyond traditional cardiovascular risk factors: a cohort study based on the China health and nutrition survey and meta-analysis. Front Cardiovasc Med 2026
6. Metabolic & GLP-1well supported · human dataAdded 10 August 2026

   Cardio beat weights for metabolic gains when paired with dieting

   Across 97 randomised trials in adults with overweight and obesity, adding exercise to a low-calorie diet improved blood glucose, insulin, insulin resistance, triglycerides, HDL cholesterol and blood pressure more than diet alone, with the benefits tied mainly to aerobic exercise, especially supervised high-intensity cycling, rather than resistance training.

   ⚠What it shows: Broad but not bulletproof: results pooled from 97 trials in adults with overweight or obesity, yet the authors rate the evidence as only moderate to low certainty. The clearest gains came from supervised high-intensity programmes, so casual unsupervised exercise may not deliver the same result.Meta-analysis · Nutr Rev

   Full breakdown →Insulin sensitivity explained →Calorie Deficit Calculator →The Effect of Aerobic or Resistance Exercise Combined With a Low-Calorie Diet Versus Diet Alone on Cardiometabolic Outcomes in Adults with Overweight and Obesity: A Systematic Review and Meta-Analysis. Nutr Rev 2026
7. Metabolic & GLP-1well supported · human dataAdded 8 August 2026

   Semaglutide's weight effect holds up in Asian adults, pooled trials find

   In a meta-analysis of five randomised trials in 2614 Asian adults with overweight or obesity, once-weekly semaglutide 2.4 mg reduced body weight by 8.20% more than placebo, with smaller waist circumference, BMI and systolic blood pressure alongside mostly mild gastrointestinal side effects.

   ⚠What it shows: Pooled data from five placebo-controlled RCTs (2614 Asian adults with overweight or obesity), all rated low risk of bias, but heterogeneity was high for weight, waist and BMI (I2 = 84%, 84% and 66%) and long-term and real-world outcomes were not assessed.Meta-analysis · Diabetes Obes Metab

   Full breakdown →Visceral fat explained →Calorie Deficit Calculator →Efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta-analysis and meta-regression of randomised trials. Diabetes Obes Metab 2025
8. Metabolic & GLP-1well supported · human dataAdded 8 August 2026

   Tirzepatide trims 16.32% of body weight in people without diabetes

   In a meta-analysis of six randomised trials in adults with overweight or obesity but without diabetes, tirzepatide cut body weight by 16.32% versus placebo, but roughly tripled the risk of nausea, diarrhoea and constipation, and more than doubled discontinuation due to adverse events.

   ⚠What it shows: Meta-analysis of six placebo-controlled RCTs in adults with overweight or obesity without diabetes; gastrointestinal side effects, serious GI events and drop-out due to adverse effects were all significantly higher than placebo.Meta-analysis · Obes Rev

   Full breakdown →Energy balance explained →Calorie Deficit Calculator →Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Obes Rev 2025
9. Metabolic & GLP-1preliminary · human dataAdded 8 August 2026

   Pilates lowered long-term blood sugar markers in type 2 diabetes

   A meta-analysis of randomised trials found Pilates lowered HbA1c by 0.96% and fasting blood sugar by 23.98 mg/dL in people with type 2 diabetes compared with standard care.

   ⚠What it shows: Meta-analysis of seven RCTs with small pooled samples (n=275 for HbA1c, n=231 for fasting glucose); Pilates formats varied across trials and larger studies are needed.Review · J Korean Biol Nurs Sci

   Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Effects of Pilates exercise on glycated hemoglobin and fasting blood sugar in type 2 diabetes: a systematic review and meta-analysis. J Korean Biol Nurs Sci 2025
10. Metabolic & GLP-1well supported · human dataAdded 8 August 2026

    One workout keeps your fat burning into tomorrow

    A single endurance workout keeps resting fat oxidation elevated on the day of exercise and into the following day, a meta-analysis finds. Total energy expended in the session and the exerciser's aerobic fitness, not exercise intensity, predicted the size of the effect.

    ⚠What it shows: Meta-analysis pooling varied exercise-study protocols; the abstract does not detail individual sample sizes; the sex difference appeared only in the fasted (postabsorptive) state; measures fat oxidation, not fat loss.Meta-analysis · J Appl Physiol (1985)

    Full breakdown →VO2max Calculator →Determinants of resting lipid oxidation in response to a prior bout of endurance exercise. J Appl Physiol (1985) 2014
11. Metabolic & GLP-1well supported · human dataAdded 8 August 2026

    Exercise cut fasting insulin across 58 trials in women

    Pooling 58 randomised trials in adult women, exercise interventions reduced fasting insulin, insulin resistance (HOMA-IR) and fasting glucose compared with control. IGF-1 rose, with no clear effect on IGFBP-3 or the IGF-1:IGFBP-3 ratio, and the evidence was graded strong only for fasting insulin and insulin resistance.

    ⚠What it shows: Systematic review and meta-analysis of 58 randomised controlled trials in adult women; no observational or Mendelian randomisation studies qualified, evidence certainty was strong for only two of the outcomes, and effects on C-peptide and HbA1c remain unexamined.Systematic review · Cancer Epidemiol Biomarkers Prev

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Linking Physical Activity to Breast Cancer Risk via Insulin/Insulin-Like Growth Factor Signaling System, Part 1: The Effect of Physical Activity on the Insulin/Insulin-Like Growth Factor Signaling System. Cancer Epidemiol Biomarkers Prev 2022
12. Metabolic & GLP-1well supported · human dataAdded 8 August 2026

    GLP-1 in a pill: big weight loss, familiar gut toll

    A meta-analysis of ten randomised trials found oral small-molecule GLP-1 receptor agonists significantly reduced body weight, waist circumference and HbA1c in adults with type 2 diabetes or obesity, and made a weight loss of 15% or more 10.61 times more likely. Gastrointestinal side effects rose sharply, but serious adverse events did not increase.

    ⚠What it shows: Meta-analysis of ten RCTs in adults with type 2 diabetes or obesity; the abstract does not report total participant numbers or trial durations, and gastrointestinal side effects were substantially more common on the drugs.Meta-analysis · Front Endocrinol (Lausanne)

    Full breakdown →Insulin sensitivity explained →Calorie Deficit Calculator →Investigation into the efficacy and safety profile of oral small-molecule GLP-1 receptor agonists in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2026
13. Metabolic & GLP-1well supported · human dataAdded 8 August 2026

    Tirzepatide improves how physically capable people feel

    A meta-analysis of six randomised trials in 4531 adults with overweight or obesity found once-weekly tirzepatide (10 or 15 mg) improved patient-reported physical function versus placebo, by 2.26 points on the SF-36 physical function domain and 10.10 points on the IWQOL-Lite-CT physical function subscale, though between-study heterogeneity was extreme.

    ⚠What it shows: Meta-analysis of six RCTs (4531 participants, 2802 on tirzepatide); outcomes were self-reported questionnaires, heterogeneity was extreme (I2 = 99.8%) and GRADE certainty only moderate due to risk of bias and inconsistency.Meta-analysis · Diabetes Obes Metab

    Full breakdown →Healthspan explained →Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis. Diabetes Obes Metab 2026
14. Metabolic & GLP-1well supported · human dataAdded 8 August 2026

    Weight loss on tirzepatide roughly doubles without diabetes

    In a meta-analysis of ten randomised trials, once-weekly tirzepatide reduced body weight by an average of 18.11 kg versus placebo in adults without diabetes, but by 9.06 kg in adults with diabetes, with mostly mild-to-moderate side effects in both groups.

    ⚠What it shows: Meta-analysis of placebo-controlled RCTs of at least 26 weeks: five trials (n=2,174) in adults with diabetes and five (n=4,467) without. The abstract does not explain why the effect differs by diabetes status.Meta-analysis · Int J Obes (Lond)

    Full breakdown →Energy balance explained →Calorie Deficit Calculator →Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis. Int J Obes (Lond) 2025
15. Metabolic & GLP-1well supported · human dataAdded 8 August 2026

    Semaglutide cuts heart-rhythm and cardiovascular risks in type 2 diabetes

    A meta-analysis of 30 randomised trials in 32490 people with type 2 diabetes found semaglutide reduced atrial fibrillation, complete heart block, death from cardiovascular causes and revascularisation compared with controls, with longer treatment showing greater benefits for heart-rhythm outcomes.

    ⚠What it shows: Meta-analysis of 30 RCTs in people with type 2 diabetes only; confidence intervals for atrial fibrillation and cardiovascular death approach the line of no effect, and the findings may not extend to people without diabetes.Meta-analysis · Front Endocrinol (Lausanne)

    Full breakdown →Heart Age Calculator →Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2025
16. Metabolic & GLP-1preliminary · human dataAdded 6 August 2026

    Night-shift fasting hints at better post-meal glucose

    A systematic review found only four randomised trials of meal-timing changes in shift workers: nearly 11 hours of overnight fasting was linked to lower post-meal glucose and non-esterified fatty acid responses versus eating and snacking at night, while insulin resistance improved in just one trial and HDL-C changed in none.

    ⚠What it shows: Systematic review of only four RCTs in adult shift workers, with different fasting windows and short durations; the authors explicitly question the robustness and generalisability of these preliminary positive signals.Review · Nutr Health

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Cardiometabolic status among shift workers under meal time regulation: A systematic review of randomized controlled trials. Nutr Health 2026
17. Metabolic & GLP-1well supported · human dataAdded 6 August 2026

    GLP-1 drugs shaved a few mmHg off blood pressure

    Pooling 30 randomised controlled trials with 37 072 overweight or obese patients, GLP-1 receptor agonists lowered systolic blood pressure by 3.37 mmHg and diastolic by 1.05 mmHg compared with placebo. The effect was consistent across diabetes status, drug formulation, follow-up duration and route of administration, with the exception of exenatide subgroups.

    ⚠What it shows: Meta-analysis of 30 RCTs in 37 072 overweight or obese patients, but blood pressure was a secondary outcome in most of them and the absolute reductions are modest; these are prescription medicines whose use and monitoring sit with a clinician.Meta-analysis · J Hypertens

    Full breakdown →Metabolic syndrome explained →Heart Age Calculator →Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials. J Hypertens 2025
18. Metabolic & GLP-1well supported · human dataAdded 6 August 2026

    GLP-1 lipid drop wasn't explained by weight loss

    A meta-analysis of placebo-controlled randomised trials found GLP-1 receptor agonists modestly reduced LDL cholesterol (mean difference -2.93 mg/dL) and cut total cholesterol by about 7 mg/dL, while triglycerides, VLDL-C and HDL-C did not change significantly. Meta-regression found weight change did not explain the LDL or total cholesterol reductions.

    ⚠What it shows: Meta-analysis of placebo-controlled RCTs with extremely high heterogeneity (I2 above 99% in the meta-regressions); the absolute lipid changes are small, most trials were not designed with lipids as the primary endpoint, and these are prescription medicines managed clinically.Meta-analysis · Curr Med Res Opin

    Full breakdown →ApoB explained →Heart Age Calculator →Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis and meta-regression of placebo controlled randomized controlled trials. Curr Med Res Opin 2025
19. Metabolic & GLP-1well supported · human dataAdded 6 August 2026

    Lifting weights improves blood sugar in type 2 diabetes

    An umbrella review of 43 systematic reviews found resistance training in adults with type 2 diabetes was associated with HbA1c reductions of roughly 0.3-0.6 percentage points, systolic blood pressure drops of about 4-7 mmHg, small lipid improvements and large gains in muscle strength.

    ⚠What it shows: Umbrella review of 43 reviews with moderate GRADE certainty for key outcomes, but substantial heterogeneity, heavy overlap of primary trials across reviews, and frequent methodological flaws in the included syntheses.Systematic review · Metabolism

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Resistance training and diabetes mellitus type 2: An umbrella review of systematic reviews and meta-analyses on glycemic and cardiometabolic outcomes. Metabolism 2026
20. Metabolic & GLP-1preliminary · human dataAdded 6 August 2026

    Breaking up sitting trimmed post-meal glucose

    In a meta-analysis of eight acute randomised crossover trials in 159 sedentary adults at metabolic risk, brief 'exercise snacks' that interrupt sitting reduced post-meal glucose iAUC by 5.69 mmol·h/L versus uninterrupted sitting. Heterogeneity was high (I² = 85%), the prediction interval crossed zero, and the insulin reduction was not statistically significant.

    ⚠What it shows: Only eight acute laboratory crossover trials, 159 sedentary adults at metabolic risk, with the glucose result resting on five trials; heterogeneity was very high, the prediction interval crossed the null, and no long-term outcomes were measured.Meta-analysis · Front Endocrinol (Lausanne)

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Acute effects of "exercise snacks" on postprandial glucose and insulin responses in populations at metabolic risk: a meta-analysis with exploratory meta-regression and vascular outcomes. Front Endocrinol (Lausanne) 2026
21. Metabolic & GLP-1preliminary · human dataAdded 6 August 2026

    Stronger semaglutide dose, only a modest extra gain

    A network meta-analysis of 24 phase 3 trials lasting at least 52 weeks found liraglutide, semaglutide and tirzepatide all reduced body weight, waist circumference and BMI versus placebo, with tirzepatide 15 mg ranked highest and liraglutide 3.0 mg producing the smallest weight loss. Semaglutide 7.2 mg ranked above semaglutide 2.4 mg on every efficacy endpoint, but the average incremental benefit was around 2-3 percentage points.

    ⚠What it shows: Network meta-analysis of 24 phase 3 RCTs in adults with BMI of 25 or above; most comparisons between doses are indirect rather than head-to-head, heterogeneity for efficacy outcomes was considerable, and few between-dose differences reached statistical significance. Says nothing about people outside these trial populations.Study · J Endocrinol Invest

    Full breakdown →GLP-1 explained →Calorie Deficit Calculator →Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis. J Endocrinol Invest 2026
22. Metabolic & GLP-1well supported · human dataAdded 6 August 2026

    Heavy lifting topped the table for HbA1c

    A network meta-analysis of 29 randomised trials in 1,301 middle-aged and older adults with type 2 diabetes found high-intensity resistance training produced the largest HbA1c reduction versus usual care (MD -0.62), ranking top of 10 exercise interventions, while moderate-intensity resistance training led on fasting glucose and high-intensity aerobic training drove the biggest gains in peak oxygen uptake. No intervention significantly reduced resting heart rate.

    ⚠What it shows: Network meta-analysis of 29 RCTs and 1,301 participants with type 2 diabetes; only the HbA1c result for high-intensity resistance training reached moderate certainty, the fasting glucose and blood pressure networks were rated low or very low, and the VO2peak network was sparse and described as exploratory.Meta-analysis · Front Public Health

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Comparative effects of different intensities of aerobic and resistance exercise on glycemic control and cardiorespiratory fitness in middle-aged older patients with type 2 diabetes: a network meta-analysis. Front Public Health 2026
23. Metabolic & GLP-1well supported · human dataAdded 6 August 2026

    Adding weights beat cardio alone for blood sugar

    Across 16 randomised trials with 1401 participants with type 2 diabetes, exercise significantly lowered HbA1c (SMD -0.46) and fasting blood glucose (SMD -0.52), with combined aerobic plus resistance training (SMD -0.71) beating aerobic exercise alone (SMD -0.32); the insulin resistance index did not improve significantly.

    ⚠What it shows: Meta-analysis of 16 randomised trials totalling 1401 people with type 2 diabetes; trial quality was assessed with the Cochrane risk-of-bias tool but individual protocols, durations and medication use varied, the BMI reduction only reached significance after removing an outlier study, and the insulin resistance index showed no significant change.Meta-analysis · Front Endocrinol (Lausanne)

    Full breakdown →Insulin sensitivity explained →Metabolic Fitness Index →Meta-analysis of the effects of exercise intervention on glucose metabolism and body composition in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne) 2026
24. Metabolic & GLP-1preliminary · human dataAdded 6 August 2026

    Massage added to lifestyle change moved the scales

    Pooling 13 randomised trials in people with simple obesity, adding massage to a lifestyle programme was associated with larger falls in body weight (mean difference -4.85 kg) and BMI (-2.65) than lifestyle change alone, along with reductions in waist circumference, total cholesterol, triglycerides, LDL cholesterol, fasting insulin and HOMA-IR. HDL cholesterol also fell rather than rose.

    ⚠What it shows: Thirteen mostly small randomised trials drawn largely from Chinese-language databases, mixing adults with children and adolescents, and with extreme statistical heterogeneity for the blood-lipid outcomes (I² up to 98.3%); effects this large from adding massage are hard to explain and need independent replication before being taken at face value.Meta-analysis · Medicine (Baltimore)

    Full breakdown →Insulin sensitivity explained →Calorie Deficit Calculator →Comparative effectiveness of massage combined with lifestyle intervention and lifestyle intervention alone for simple obesity: A systematic review and meta-analysis. Medicine (Baltimore) 2025

Back to the full archive · this week’s studies